PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.

Recent developments in the health sector highlight diverse changes from drug pricing initiatives by Bristol Myers and Pfizer ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

A recalled sickle cell drug is drawing new scrutiny from attorneys who say it may have done more harm than good, possibly ...

The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...

Drugmaker Pfizer is warning doctors that it expects to run low on supplies of Bicillin L-A, a long-acting injection of the ...

Pfizer has received approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control ...

Top regulators like the US FDA and EMA are fast-tracking more Chinese drugs, granting priority review and breakthrough ...

Discover the current pipeline candidates advancing through the clinic for the treatment of sickle cell disease.

Apixaban would still cost patients 9 times more through the Eliquis 360 Support program than with commercial insurance.

Ovarian Cancer Drugs Market grows as FDA, EMA fast-track advanced-stage therapies, boosting global approvals and innovation. Anurag Tiwari Orion Market Research Pvt Ltd + +91 91798 28694 email us here ...